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Introduction
Primary antibody deficiency (PAD) is the most common 
group of primary immunodeficiency disorders (PID). It results 
from various defects in the development and function of the 
B-cell lineage [1]. The spectrum of PAD is broad, ranging 
from severely reduced serum Ig titers and totally absent B cells 
to selective antibody deficiency and normal serum Ig [2]. 
Hypogammaglobulinemia, or antibody deficiency, is the 
hallmark of PAD. Affected individuals share a clinical 
phenotype with common features such as chronic and recurrent 
infections, chronic inflammation, and autoimmunity [2], 
leading to recurrent hospitalization and impaired quality of 
life [3,4]. Patients with PAD also tend to develop malignancies 
and lymphoproliferative disorders [5,6].    
PAD often arises as a result of defects in early B-cell 
development in bone marrow and class switch recombination 
(CSR) or terminal B-cell differentiation in secondary lymphoid 
organs [1,7]. Defects in early B-cell development in bone 
417
 Abstract
Background: Primary antibody deficiency (PAD) is the most common group of primary immunodeficiency disorders (PID), with a broad 
spectrum of clinical features ranging from severe and recurrent infections to asymptomatic disease.
Objectives: The current study was performed to evaluate and compare demographic and clinical data in the most common types of PAD.
Materials and Methods: We performed a retrospective review of the medical records of all PAD patients with a confirmed diagnosis of 
common variable immunodeficiency (CVID), hyper IgM syndrome (HIgM), selective IgA deficiency (SIgAD), and X-linked agammaglobulinemia 
(XLA) who were diagnosed during the last 30 years at the Children’s Medical Center, Tehran, Iran.
Results: A total number of 280 cases of PAD (125 CVID, 32 HIgM, 63 SIgAD, and 60 XLA) were enrolled in the study. The median (range) age 
at the onset of disease in CVID, HIgM, SIgAD, and XLA was 2 (0-46), 0.91 (0-9), 1 (0-26), and 1 (0-10) years, respectively. Gastrointestinal 
infections were more prevalent in CVID patients, as were central nervous system infections in XLA patients. Autoimmune complications 
were more prevalent in HIgM patients, malignancies in CVID patients, and allergies in SIgAD patients. The mortality rate for CVID, HIgM, 
and XLA was 27.2%, 28.1%, and 25%, respectively. No deaths were reported in SIgAD patients. 
Conclusions: SIgAD patients had the best prognosis. While all PAD patients should be monitored for infectious complications, special 
attention should be paid to the finding of malignancy and autoimmune disorders in CVID and HIgM patients, respectively.
Key words: Common variable immunodeficiency. Immunoglobulin A deficiency. Infection. Hyper-IgM syndrome. X-linked agammaglobulinemia.
 Resumen
Antecedentes: Las inmunodeficiencias humorales primarias (PAD) es el grupo más frecuente de inmunodeficiencias primarias (IDP), y engloba 
un amplio espectro de características clínicas, que van desde los pacientes con infecciones graves y recurrentes a los casos asintomáticos.
Objetivos: El presente estudio se realizó para evaluar y comparar los datos demográficos y clínicos de los tipos más comunes de PAD.
Materiales y Métodos: Se revisaron retrospectivamente, las historias clínicas de todos los pacientes con PAD con un diagnóstico confirmado 
de: inmunodeficiencia variable común (CVID), síndrome de hiper IgM (HIgM), deficiencia selectiva de IgA (SIgAD),y de agammaglobulinemia 
ligada al cromosoma X (XLA), que fueron diagnosticados durante los últimos 30 años, en el Centro Médico de Niños, Teherán, Irán.
Resultados: Se incluyeron en este estudio un total de 280 casos de PAD, englobando 125 pacientes con CVID, 32 HIgM, 63 SIgAD, y 60 
pacientes con XLA. La mediana (rango) de edad al inicio de la enfermedad en la CVID, HIgM, SIgAD y XLA fue: 2 (0-46), 0,91 (0-9), 1 
(0-26) y 1 (0-10) años, respectivamente. Las infecciones gastrointestinales fueron más frecuentes en los pacientes con CVID, mientras que 
las infecciones del sistema nervioso central lo fueron en la XLA. Las complicaciones autoinmunes fueron más prevalentes en los pacientes 
con HIgM, los tumores malignos en las CVID y las enfermedades alérgicas en las SIgAD. La tasa de mortalidad de CVID, HIgM y XLA fue 
27,2%, 28,1% y 25%, respectivamente. No hubo mortalidad en el grupo de pacientes con SIgAD.  
Conclusiones: Los pacientes con SIgAD tuvieron el mejor pronóstico. Aunque todos los pacientes con PAD deben ser controlados 
estrechamente para evitar las complicaciones infecciosas, se debe prestar especial atención a la aparición de enfermedades malignas y 
autoinmunes en los pacientes con CVID y HIgM, respectivamente.
Palabras clave: Inmunodeficiencia variable común. Deficiencia selectiva de inmunoglobulina A. Infección. Síndrome hiper IgM. 
Agammaglobulinemia ligada al cromosoma X.
marrow result in agammaglobulinemia (X-linked or autosomal 
recessive), which is characterized by profound reduction 
in serum Ig, markedly reduced mature B cell counts in the 
peripheral circulation, and early onset of recurrent bacterial 
infections [8-11]. Defects in CSR result in low serum levels 
of IgG and IgA and normal or elevated levels of serum IgM. 
Recurrent bacterial infections are common in PAD patients 
with defects in CSR (hyper-IgM syndrome) [12,13]. Defects 
in several genes, including CD40 ligand (CD40L), CD40, 
inhibitor of κ light polypeptide gene enhancer in B-cells, kinase 
gamma (IKBKG), activation-induced cytidine deaminase 
(AID), and uracil N glycosylase (UNG) have been known to 
cause CSR defects [12]. Defects in terminal stages of B-cell 
development that are controlled by genetic signatures result 
in antibody deficiency with isolated Ig class deficiency, 
namely, selective IgA deficiency (SIgAD), or deficiency in 
all 3 Ig classes, namely, common variable immunodeficiency 
(CVID) [14,15]. SIgAD is the most common primary 
immunodeficiency in Caucasians [16-18], whereas CVID is the 
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most prevalent symptomatic PAD [19]. Although most cases of 
SIgAD are asymptomatic, symptomatic SIgAD shares many 
clinical features with CVID [20]. A common genetic basis for 
SIgAD and CVID has been suggested based on co-occurrence 
in members of the same family and on the similarity in the 
underlying B-cell defects. Progression from SIgAD to CVID 
has also been reported [20,21].   
Demographic and clinical data have been reported for 
various types of PAD [22,23]. However, studies comparing 
these findings between various PAD types in the same clinical 
setting are lacking. Moreover, physicians’ poor awareness 
of these disorders remains a major cause of morbidity and 
mortality in affected patients [24,25]. The current study was 
performed to evaluate and compare the demographic and 
clinical data of the most common types of PAD in patients 
who were diagnosed and treated in a tertiary referral hospital 
in Iran over a 30-year period.
Methods
Patient Selection
We reviewed the medical records of all patients diagnosed 
with PAD between March 1983 and March 2013 at the 
Children’s Medical Center, Tehran, Iran. Patients with CVID, 
HIgM, SIgAD, and XLA were enrolled. Other types of PAD 
were excluded from the study because of low prevalence or 
clinical insignificance. PAD was diagnosed according to the 
criteria of the Pan-American Group for Immunodeficiency and 
the European Society for Immunodeficiencies [26]. Secondary 
causes of immunodeficiency were ruled out in all patients. 
The study was approved by the Ethics Committee of Tehran 
University of Medical Science. All patients or their legal 
guardians were asked to complete an informed consent form. 
Patients’ names were replaced with codes before data entry.
Data Collection
Using patients’ medical records, we completed a 2-page 
questionnaire to record demographic data, clinical manifestations, 
past medical history, immunologic findings, long-term follow-
up, complications, and disease outcome. All questionnaires were 
then evaluated, and those with missing data were completed by 
the immunologist responsible for the patient’s management. 
Finally, patient data were included in the study after the diagnosis 
of PAD was confirmed by another immunologist. 
Laboratory Testing
Blood samples were tested for Ig levels and CD 
markers and compared with their normal quantitative range. 
Other laboratory tests included a complete blood count, 
isohemagglutinin titer, and Schick test. Measurements of B-cell 
and T-cell subsets of patients diagnosed before 1993 were 
repeated using flow cytometry, as the method used before 1993 
was based on rosette formation. DNA mutation analysis was 
also performed in some cases. Paraclinical evaluations such 
as pulmonary function, high-resolution computed tomography, 
endoscopy, and biopsy were performed as indicated. Cause of 
death was recorded from the death certificate.
Data Analysis
Data were analyzed using SPSS version 20 (IBM Corp). 
The Kolmogorov-Smirnov test was performed to evaluate the 
normality of distribution. Data are presented as mean (SD) if 
normally distributed and as median (range) if nonnormally 
distributed. A 1-way analysis of variance was used to 
investigate probable differences in quantitative variables 
between PAD groups. A post hoc analysis was performed using 
the Scheffe method to further evaluate the differences between 
pairs of PAD disorders. The chi-square or Fisher exact test 
was performed to evaluate differences in categorical variables 
between the PAD groups, as indicated. A linear regression 
analysis was used to determine the association between the 
date of onset of disease and diagnostic delay. Probabilities 
of survival after diagnosis of PAD were estimated using the 
Kaplan-Meier method.
Results
Patient Characteristics
The study population comprised 280 cases of PAD 
(209 male and 71 female) distributed as 125 CVID patients 
(44.6%), 63 SIgAD patients (22.5%), 60 XLA patients (21.4%), 
and 32 HIgM patients (11.4%). Four cases initially diagnosed 
as SIgAD later progressed to CVID. Median age was 16.5 
(1-63) years. The median age of patients at onset of disease 
was 1 (0.01-46) year. By the age of 2 years, 46.4% of CVID 
patients, 52.3% of SIgAD patients, 75% of HIgM patients, and 
Figure 1. Association between the date of onset of disease and 
diagnostic delay in patients with common variable immunodeficiency 
(CVID), hyper IgM syndrome (HIgM), selective IgA deficiency (SIgAD), 
and X-linked agammaglobulinemia (XLA).
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65% of XLA patients had experienced the first manifestation 
of disease, indicating earlier presentation of HIgM and XLA 
compared with CVID and SIgAD. By the age of 5 years, 69.6% 
of CVID patients, 73% of SIgAD patients, 81.2% of HIgM 
patients, and 86.6% of XLA patients had experienced the first 
manifestation of disease. While 4% of CVID patients and 3.1% 
of SIgAD patients experienced the first manifestation of disease 
after 18 years of age, all of the HIgM and XLA patients had 
their first manifestation before 10 years of age. The median 
age of the patients at the time of diagnosis was 6 (0.08-54) 
years. The median diagnostic delay was 2.83 (0-51) years. 
Patients were followed for a total of 1652 patient-years. The 
1-way analysis of variance revealed a significant difference 
between the 4 types of PAD with respect to age, age at onset, 
age at diagnosis, and diagnostic delay. Patients with XLA had 
a significantly lower age at onset than patients with CVID 
(P=.03). Table 1 compares the characteristics and demographic 
data of CVID, HIgM, SIgAD, and XLA patients. There was 
a significant reverse association between the date of onset 
and diagnostic delay in all types of PAD (P<.001) (Figure 1). 
There were no significant differences between the 4 types of 
PAD for this association. 
First Clinical Manifestation
Infections were the most common presenting feature of 
PAD at onset. Out of 280 patients, 251 (89.6%) experienced 
various types of infection as their first presentation of disease. 
As shown in Table 2, there were significant differences between 
various types of PAD for the prevalence of infection as the first 
manifestation of PAD (P=.005). More than 90% of patients with 
CVID, HIgM, and XLA experienced infectious manifestations 
at disease onset (92%, 93.8%, and 95% respectively). This rate 
was considerably lower in patients with SIgAD, of whom 22.2% 
experienced a noninfectious manifestation as the presenting 
feature of their disease (P<.001 for SIgAD vs CVID, HIgM, 
and XLA). Respiratory tract infection was the most common 
presenting feature (observed in 197 patients [70.4%]) followed 
by diarrhea (41 patients [14.6%]) and allergy (12 [4.2%]). 
Patients with SIgAD were significantly more likely to present 
with allergy than patients with other types of PAD (P<.001, 
P=0.007, and P<.001 for SIgAD vs CVID, HIgM, and XLA). 
Other manifestations were observed in fewer than 10 cases. 
Table 2 shows the most common presenting features of PAD 
for the different types of PAD.
Clinical Manifestations and Complications
Clinical manifestations and complications of PAD during 
the course of the disease included infection, autoimmunity, 
malignancy, enteropathy, allergy, and lymphoproliferative 
disorders. 
Infectious complications were observed in all cases except 
1 patient with SIgAD. Infections of the respiratory system 
were the most common (244 patients [87.1%]), followed by 
infections of the gastrointestinal tract (142 patients [50.7%]), 
skin (105 [37.5%]), skeletal system (37 [13.2%]), urinary 
tract (27 [9.6%]), and central nervous system (25 [8.9%]). 
Table 3 compares infections in various systems for these 
4 PAD types. 
Ta
bl
e 
3.
 C
om
pa
ris
on
 o
f I
nf
ec
tio
ns
 A
cc
or
di
ng
 to
 Ty
pe
 o
f A
nt
ib
od
y 
De
fic
ie
nc
y 
 
C
V
ID
 
H
Ig
M
 
S
Ig
A
D
 
X
L
A
 
To
ta
l 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
 
(n
=
12
5)
 
(n
=
32
) 
(n
=
63
) 
(n
=
60
) 
 
B
et
w
ee
n 
C
V
ID
 
C
V
ID
 
C
V
ID
 
H
Ig
M
 
H
Ig
M
 
S
Ig
A
D
 
 
 
 
 
 
 
G
ro
up
s 
vs
 H
Ig
M
 
vs
 S
Ig
A
D
 
vs
 X
L
A
 
vs
 S
Ig
A
D
 
vs
 X
L
A
 
vs
 X
L
A
  
R
es
pi
ra
to
ry
,  
N
o.
 (
%
) 
11
7 
(9
3.
6%
) 
29
 (
90
.6
%
) 
47
 (
74
.6
%
) 
51
 (
85
%
) 
24
4 
(8
7.
1%
) 
.0
03
a  
.6
96
 
<
.0
01
a  
.1
04
 
.1
01
 
.5
32
 
.2
27
G
as
tr
oi
nt
es
ti
na
l, 
 
N
o.
 (
%
) 
83
 (
66
.4
%
) 
16
 (
50
%
) 
20
 (
31
.7
%
) 
23
 (
38
.3
%
) 
14
2 
(5
0.
7%
) 
<
.0
01
a  
.1
31
 
<
.0
01
a  
<
.0
01
a  
.1
31
 
.3
91
 
.5
64
C
ut
an
eo
us
,  
N
o.
 (
%
) 
48
 (
38
.4
%
) 
15
 (
46
.9
%
) 
15
 (
23
.8
%
) 
27
 (
45
%
) 
10
5 
(3
7.
5%
) 
.0
48
a  
.3
89
 
.1
1 
.3
51
 
.0
45
a  
.8
63
 
.0
25
a
C
en
tr
al
 n
er
vo
us
  
sy
st
em
, N
o.
 (
%
) 
13
 (
10
.4
%
) 
0 
0 
12
 (
20
%
) 
25
 (
8.
9%
) 
<
.0
01
a  
.0
71
 
.0
05
a  
.1
19
 
1 
.0
06
a  
<
.0
01
a
S
ke
le
ta
l s
ys
te
m
,  
N
o.
 (
%
) 
19
 (
15
.2
%
) 
5 
(1
5.
6%
) 
2 
(3
.2
%
) 
11
 (
18
.3
%
) 
37
 (
13
.2
%
) 
.0
47
a  
1 
.0
13
a  
.1
08
 
.0
41
a  
1 
.0
07
a
U
ri
na
ry
 tr
ac
t, 
 
N
o.
 (
%
) 
16
 (
12
.8
%
) 
3 
(9
.3
%
) 
2 
(3
.2
%
) 
2 
(3
.3
%
) 
27
 (
9.
6%
) 
.0
65
 
.7
66
 
.0
36
a  
.0
6 
.3
31
 
.3
37
 
1
M
ul
ti
pl
e 
si
te
s,
  
N
o.
 (
%
) 
10
3 
(8
2.
4%
) 
22
 (
68
.8
%
) 
15
 (
23
.8
%
) 
39
 (
65
%
) 
17
9 
(6
3.
9%
) 
<
.0
01
a  
.1
43
 
<
.0
01
a  
.0
14
a  
<
.0
01
a  
.8
95
 
<
.0
01
a
Ab
br
ev
ia
tio
ns
: C
VI
D,
 c
om
m
on
 v
ar
ia
bl
e 
im
m
un
od
efi
cie
nc
y; 
HI
gM
, h
yp
er
-Ig
M
 s
yn
dr
om
e;
 S
Ig
AD
, s
el
ec
tiv
e 
Ig
A 
de
fic
ie
nc
y; 
XL
A,
 X
-li
nk
ed
 a
ga
m
m
ag
lo
bu
lin
em
ia
.
a S
ta
tis
tic
al
ly 
sig
ni
fic
an
t.
PAD in Iran
J Investig Allergol Clin Immunol 2015; Vol. 25(6): 416-425© 2015 Esmon Publicidad
421
Ta
bl
e 
4.
 C
om
pa
ris
on
 o
f C
lin
ica
l M
an
ife
st
at
io
ns
 A
cc
or
di
ng
 to
 Ty
pe
 o
f P
rim
ar
y A
nt
ib
od
y 
De
fic
ie
nc
y 
 
C
V
ID
 
H
Ig
M
 
S
Ig
A
D
 
X
L
A
 
To
ta
l 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
 
(n
=
12
5)
 
(n
=
32
) 
(n
=
63
) 
(n
=
60
) 
(n
=
28
0)
 
B
et
w
ee
n 
C
V
ID
 
C
V
ID
 
C
V
ID
 
H
Ig
M
 
H
Ig
M
 
S
Ig
A
D
 
 
 
 
 
 
 
G
ro
up
s 
vs
 H
Ig
M
 
vs
 S
Ig
A
D
 
vs
 X
L
A
 
vs
 S
Ig
A
D
 
vs
 X
L
A
 
vs
 X
L
A
  
In
fe
ct
io
us
,  
N
o.
 (
%
) 
12
4 
(9
9.
2%
) 
32
 (
10
0%
) 
58
 (
98
.1
%
) 
56
 (
93
.3
%
) 
27
0 
(9
6.
4%
) 
.0
28
a  
1 
.0
16
a  
.0
38
a  
.1
63
 
.2
93
 
1
A
ut
oi
m
m
un
it
y,
  
N
o.
 (
%
) 
38
 (
30
.4
%
) 
13
 (
40
.6
%
) 
14
 (
22
.2
%
) 
11
 (
18
.3
%
) 
76
 (
27
.1
%
) 
.0
81
 
.3
73
 
.3
12
 
.1
18
 
.1
01
 
.1
31
 
.7
55
M
al
ig
na
nc
y,
  
N
o.
 (
%
) 
10
 (
8%
) 
1 
(3
.1
%
) 
0 
0 
11
 (
3.
9%
) 
.0
14
a  
.4
63
 
.0
32
a  
.0
31
a  
.3
36
 
.3
47
 
1
E
nt
er
op
at
hy
,  
N
o.
 (
%
) 
22
 (
17
.6
%
) 
3 
(9
.4
%
) 
15
 (
23
.8
%
) 
6 
(1
0%
) 
46
 (
16
.4
%
) 
.1
33
 
.4
15
 
.4
14
 
.2
58
 
.1
04
 
.9
23
 
.0
72
A
ll
er
gy
,  
N
o.
 (
%
) 
39
 (
31
.2
%
) 
6 
(1
8.
8%
) 
43
 (
68
.3
%
) 
10
 (
16
.7
%
) 
98
 (
35
%
) 
<
.0
01
a  
.2
41
 
<
.0
01
a  
.0
55
 
<
.0
01
a  
.8
01
 
<
.0
01
a
L
ym
ph
op
ro
li
fe
ra
ti
ve
,  
N
o.
 (
%
) 
67
 (
53
.6
%
) 
21
 (
65
.6
%
) 
6 
(9
.5
%
) 
15
 (
25
%
) 
10
9 
(3
8.
9%
) 
<
.0
01
a  
.3
06
 
<
.0
01
a  
<
.0
01
a  
<
.0
01
a  
<
.0
01
a  
.0
41
a
Ab
br
ev
ia
tio
ns
: C
VI
D,
 c
om
m
on
 v
ar
ia
bl
e 
im
m
un
od
efi
cie
nc
y; 
HI
gM
, h
yp
er
-Ig
M
 s
yn
dr
om
e;
 S
Ig
AD
, s
el
ec
tiv
e 
Ig
A 
de
fic
ie
nc
y; 
XL
A,
 X
-li
nk
ed
 a
ga
m
m
ag
lo
bu
lin
em
ia
.
a S
ta
tis
tic
al
ly 
sig
ni
fic
an
t.
Ta
bl
e 
5.
 M
ai
n 
Co
m
pl
ica
tio
ns
 A
cc
or
di
ng
 to
 Ty
pe
 o
f P
rim
ar
y A
nt
ib
od
y 
De
fic
ie
nc
y 
 
C
V
ID
 
H
Ig
M
 
S
Ig
A
D
 
X
L
A
 
To
ta
l 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
P 
V
al
ue
 
 
(n
=
12
5)
 
(n
=
32
) 
(n
=
63
) 
(n
=
60
) 
(n
=
28
0)
 
B
et
w
ee
n 
C
V
ID
 
C
V
ID
 
C
V
ID
 
H
Ig
M
 
H
Ig
M
 
S
Ig
A
D
 
 
 
 
 
 
 
G
ro
up
s 
vs
 H
Ig
M
 
vs
 S
Ig
A
D
 
vs
 X
L
A
 
vs
 S
Ig
A
D
 
vs
 X
L
A
 
vs
 X
L
A
  
B
ro
nc
hi
ec
ta
si
s 
43
 (
34
.4
%
) 
3 
(9
.3
%
) 
1 
(1
.6
%
) 
12
 (
20
%
) 
59
 (
21
.1
%
) 
<
.0
01
a  
.0
04
a  
<
.0
01
a  
.0
66
 
.1
09
 
.3
08
 
.0
02
a
C
ir
rh
os
is
 
3 
(2
.4
%
) 
1 
(3
.1
%
) 
1 
(1
.6
%
) 
4 
(6
.6
%
) 
9 
(3
.2
%
) 
.3
76
 
1 
1 
.2
12
 
1 
.6
54
 
.2
A
IH
A
 
5 
(4
%
) 
4 
(1
2.
4%
) 
0 
(0
%
) 
0 
(0
%
) 
9 
(3
.2
%
) 
.0
04
a  
.0
84
 
.1
71
 
.1
76
 
.0
11
a  
.0
12
a  
1
JR
A
 
3 
(2
.4
%
) 
4 
(1
2.
5%
) 
0 
(0
%
) 
4 
(6
.6
%
) 
11
 (
3.
9%
) 
.0
13
a  
.0
32
a  
.5
52
 
.2
16
 
.0
11
a  
.4
42
 
.0
53
IT
P 
5 
(4
%
) 
5 
(1
5.
5%
) 
0 
(0
%
) 
3 
(5
%
) 
13
 (
4.
6%
) 
.0
06
a  
.0
3a
 
.1
7 
.7
15
 
.0
03
a  
.1
21
 
.1
13
L
ym
ph
ad
en
op
at
hy
 
44
 (
35
.2
%
) 
13
 (
40
.6
%
) 
3 
(4
.8
%
) 
4 
(6
.6
%
) 
64
 (
22
.8
%
) 
<
.0
01
a  
.7
16
 
<
.0
01
a  
<
.0
01
a  
<
.0
01
a  
<
.0
01
a  
.7
15
H
ep
at
om
eg
al
y 
39
 (
31
.2
%
) 
9 
(2
8.
1%
) 
0 
(0
%
) 
11
 (
18
.3
%
) 
59
 (
21
.1
%
) 
<
.0
01
a  
.9
03
 
<
.0
01
a  
.0
95
 
<
.0
01
a  
.4
12
 
<
.0
01
a
S
pl
en
om
eg
al
y 
50
 (
40
%
) 
11
 (
34
.4
%
) 
0 
(0
%
) 
7 
(1
1.
7%
) 
68
 (
24
.3
%
) 
<
.0
01
a  
.7
04
 
<
.0
01
a  
<
.0
01
a  
<
.0
01
a  
.0
19
a  
.0
05
a
E
nt
er
op
at
hy
  
26
 (
20
.8
%
) 
3 
(9
.3
%
) 
5 
(7
.9
%
) 
5 
(8
.3
%
) 
39
 (
13
.9
%
) 
.0
3a
 
.2
01
 
.0
41
a  
.0
33
a  
1 
1 
.9
35
F
T
T
 
26
 (
20
.8
%
) 
6 
(1
8.
7%
) 
1 
(1
.6
%
) 
4 
(6
.6
%
) 
37
 (
13
.2
%
) 
<
.0
01
a  
.7
97
 
<
.0
01
a  
.0
18
a  
.0
05
a  
.0
9 
.2
Ab
br
ev
ia
tio
ns
: A
IH
A,
 a
ut
oi
m
m
un
e 
he
m
ol
yt
ic 
an
em
ia
; C
VI
D,
 c
om
m
on
 v
ar
ia
bl
e 
im
m
un
od
efi
cie
nc
y; 
FT
T, 
fa
ilu
re
 to
 th
riv
e;
 H
Ig
M
, h
yp
er
-Ig
M
 s
yn
dr
om
e;
 IT
P, 
im
m
un
e 
(id
io
pa
th
ic)
 th
ro
m
bo
cy
to
pe
ni
a 
pu
rp
ur
a;
 
JR
A,
 ju
ve
ni
le
 rh
eu
m
at
oi
d 
ar
th
rit
is;
 S
Ig
AD
, s
el
ec
tiv
e 
Ig
A 
de
fic
ie
nc
y; 
XL
A,
 X
-li
nk
ed
 a
ga
m
m
ag
lo
bu
lin
em
ia
.
a S
ta
tis
tic
al
ly 
sig
ni
fic
an
t.
Mohammadinejad P, et al.
J Investig Allergol Clin Immunol 2015; Vol. 25(6): 416-425 © 2015 Esmon Publicidad
Autoimmunity was observed in 76 patients (27.1%), 
enteropathy in 46 patients (16.4%), allergy in 98 patients 
(35%), and lymphoproliferative complications in 109 patients 
(38.9%). Allergic manifestations were observed in 43 SIgAD 
patients (68.3%), 39 CVID patients (31.2%), 6 HIgM patients 
(18.8%), and 9 XLA patients (15%). These manifestations were 
observed more significantly in SIgAD than in other types of 
PAD (P<.001 for SIgAD vs CVID, HIgM, and XLA). The most 
common allergic manifestation was drug reactions (24 PAD 
patients [8.6%]), followed by urticaria (20 [7.1%]), eczema 
(19 [6.8%]), asthma (15 [5.4%]), food allergy (12 [4.3%]), 
allergic rhinitis (11 [3.9%]), allergic conjunctivitis (10 [3.6%]), 
and atopic dermatitis (8 [2.9%]). Other allergic manifestations 
were observed in fewer than 5 cases. Tables 4 and 5 show the 
various types of clinical manifestations and complications 
among the 4 PAD types. 
Malignancy
Malignancy was observed in 11 PAD patients (3.9%): 10 
(8%) CVID patients and 1 (3.1%) HIgM patient (P=.461, .032, 
and .031 for CVID vs HIgM, SIgAD, and XLA, respectively). 
The 11 patients included 4 cases of CVID with non-Hodgkin 
lymphoma, 3 cases of CVID with gastric adenocarcinoma, 2 
cases of CVID and 1 case of HIgM with Hodgkin lymphoma, 
and 1 case of CVID with breast cancer.
Mortality
Out of 280 PAD patients, 58 (20.7%) had died by the end 
of follow-up. A total of 107 patients (60.7%) were known to 
be alive, and 52 patients (18.6%) could not be located during 
the last 6 months of follow-up. No deaths were reported among 
patients with SIgAD. The mortality rate was not significantly 
different in patients with CVID, HIgM, and XLA (27.2%, 
28.1%, and 25% respectively). The cause of death was 
respiratory failure in 19 cases, liver failure in 6 cases, cardiac 
arrest in 8 cases, septic shock in 6 cases, massive hemorrhage 
in 2 cases, gastric cancer in 2 cases, Hodgkin lymphoma in 
2 cases, non-Hodgkin lymphoma in 1 case, Kawasaki disease 
in 1 case, encephalitis in 1 case, and meningitis in 1 case. The 
cause of death was unknown in 9 cases. 
There were no significant differences in diagnostic delay 
between patients who died and patients who lived (4.59 [6.11] 
years vs 5.73 [7.21] years, P=.26). In contrast, the number of 
hospitalizations was significantly higher in patients who died 
(4.72 [2.17] vs 3.22 [3.39], P=.021). The number of episodes 
of infection was also significantly higher in patients who died 
(20.29 [17.19] vs 11.51 [11.75], P=.007).
No significant differences were found between patients 
who lived and patients who died in terms of consanguinity, 
family history of PID, family history of recurrent infections, 
family history of death at an early age, family history of 
malignancy, and family history of allergy. However, a family 
history of autoimmunity was more common in patients who 
lived (12.2% vs 0%, P=.025). Survival curves for CVID, 
SIgAD, HIgM, and XLA patients are presented in Figure 2. 
The log-rank test revealed significant differences in the survival 
only between SIgAD patients and the remaining 3 types of 
PAD (P<.001).
Discussion
We present the demographic and clinical data of 280 
PAD patients diagnosed in a tertiary referral hospital over 
a 30-year period. CVID, which is the most symptomatic 
type of PAD [27], was the most prevalent type of PAD in 
the present study, affecting nearly half of the population. 
Although this finding contrasts with the results of European 
studies reporting SIgAD to be the most common type of 
PAD [28], it is consistent with the results of studies performed 
in Australia and Japan [29,30]. Most reported cases of SIgAD 
are asymptomatic, probably because studies from Asian 
countries, including the current study, are hospital-based and 
do not include asymptomatic cases [31]. 
In our study, the median age at disease onset was 1 year, 
and the median diagnostic delay was 2 years and 10 months. 
In a study on English PAD patients, the median age at onset 
was 41 years and the median diagnostic delay 2 years [32]. The 
higher prevalence of PAD among younger Iranian individuals 
may be a consequence of high rates of consanguineous 
marriages and a higher prevalence of autosomal recessive 
forms, especially among CVID patients [33-35]. Interestingly, 
XLA patients were still younger at disease onset than CVID 
patients, whose disease presented in childhood, thus pointing 
to probable clinical involvement in the diagnosis of patients 
with suspected PAD. Diagnostic delay in patients referred to 
our center was similar to that reported for European patients, 
indicating acceptable awareness among physicians and access 
to diagnostic methods at the Children’s Medical Center hospital 
in Tehran, Iran [36]. 
Infection was the first sign of disease in about 90% of 
our study population. Infection is the most prominent clinical 
feature of all types of PAD [2,28]. Respiratory tract infection 
was the most prevalent manifestation at onset, followed by 
gastrointestinal tract infection, except for SIgAD patients, in 
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Figure 2. Survival Curve for Common Variable Immunodeficiency 
(CVID), Hyper-IgM Syndrome (HIgM), Selective IgA Deficiency (SIgAD), 
and X-Linked Agammaglobulinemia (XLA).
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whom allergic complications were the second most prevalent 
initial manifestation after respiratory tract infection. Although 
the frequency of allergic disorders as the presenting feature of 
PAD has not been evaluated, a tendency toward allergy has 
been reported among SIgAD patients [16,37].
Infection was also the most common complication during 
the course of disease in our study population. All patients 
except for 1 SIgAD patient experienced at least 1 serious 
infection. Although it was reported that up to 90% of SIgAD 
patients are asymptomatic at onset, about 80% of these 
patients are predicted to experience infections or allergic and 
autoimmune disorders during the course of their disease [38]. 
Infections of the upper and lower respiratory tracts were the 
most common infectious complications in the current study. 
Respiratory tract infections were observed in 74% of patients 
with SIgAD, and in more than 85% of patients with CVID, 
HIgM, and XLA. Other authors report similar findings for 
the prevalence of respiratory tract infection in patients with 
CVID (76%) [22], HIgM (80%) [23], and XLA (85%) [39]. 
The prevalence of these infections among SIgAD patients in 
the present study was higher than reported by Macpherson 
et al [40], who found that most cases were asymptomatic, 
in contrast with the findings of the present study. However, 
almost all reports agree that respiratory tract infection is the 
most common type of infection among SIgAD patients [37,40]. 
Allergy was the most common noninfectious complication, 
especially in SIgAD patients, followed by autoimmunity, which 
was observed in 27% of patients. This finding is similar to that 
of Sarmiento et al [41], who reported autoimmunity in 23% of 
PAD patients. Malignancy was also a major complication in 
our study population and was observed most commonly among 
CVID patients. Consistent with this finding, Vajdic et al [29] 
evaluated the prevalence of malignancy among various types 
of PAD and found that CVID patients were at a much higher 
risk of developing cancer than other PAD patients. 
The mortality rate in CVID, HIgM, and XLA was about 
25% in our study population. No deaths were observed among 
SIgAD patients, consistent with reports of very low mortality 
due to complications of SIgAD [16]. The mortality rate in 
XLA patients was similar to that reported in 2 studies on the 
outcome of XLA published in 1985 and 1993 (17% and 25%, 
respectively) [42,43]. However, a study performed in 2002 
on the outcome of Italian XLA patients showed a much lower 
mortality rate (1.4%) than the one we report here, indicating 
poor management of this disorder among Iranian XLA patients 
[44,45]. Cunningham-Rundles and Bodian [22] reported a 
mortality rate of 22% among American CVID patients, which 
is in agreement with the findings of the present study for a 
similar follow-up period. It is likely that the true mortality rate 
of our study population is higher than reported, since around 
18% of patients could not be located during the last 6 months 
of the follow-up period [46]. 
The present study provides long-term follow-up and a 
valid comparison of the major types of PAD. However, several 
limitations should be addressed. First, genetic analysis is not 
routinely available in Iran, with the result that samples have 
to be sent overseas for evaluation of probable genetic defects. 
Hence, underlying molecular defects are not determined 
in most cases. Second, our hospital is a referral center for 
patients with suspected immunodeficiency in Iran, a Middle 
Eastern country with high rates of consanguineous marriages; 
therefore, its findings may not be a true reflection of PAD in 
other regions of the world. Third, since some patients were lost 
to follow-up, true mortality rates may be significantly different 
from those presented here.
In conclusion, observation of recurrent and/or severe 
infections as the most prevalent feature of PAD should lead 
the physician to suspect these disorders. Greater awareness 
facilitates timely diagnosis, which in turn decreases morbidity 
and mortality. Of the 4 most common types, SIgAD is more 
likely to become complicated by allergic and autoimmune 
conditions but less likely to be associated with severe and 
recurrent infections than other types of PAD. Patients with 
CVID are also at a much higher risk of malignancy than 
patients with other types of PAD.
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